PDCD1 and melanoma: Our stroma score also separated advanced-stage melanoma patients who achieved disease control (DC) from those with progressive disease (PD) in the cohort by Riaz et al.18 who received anti-PD-1 as first-line immunotherapy (i.e., ipi-naive; n = 19 patients; Fig. 3f).